by the Bellani (Belani) clinical efficacy and safety, pemetrexed or placebo immediately given clinical trials of international
by the Bellani (Belani) clinical efficacy and safety, pemetrexed or placebo immediately given clinical trials of international multi center led the comparison of advanced lung cancer after first-line chemotherapy showed that pemetrexed maintenance therapy in patients with overall survival of 13.4 months, while the placebo group survival for 10.6 months (P=0.012). This means that 21% of the risk of death can be reduced by the use of Sai as a maintenance therapy. As pemetrexed in the first-line treatment of the study as well as in the maintenance treatment of lung adenocarcinoma and its effect is the best, the median survival was 15.5 months (P=0.002) but for the maintenance treatment of lung squamous cell carcinoma has no difference with placebo, the median survival was only 9.9 months (P=0.67).
it is worth mentioning that pemetrexed maintenance therapy rarely serious side effects, 3/4 neutropenia and anemia incidence rate of only 3%, the fatigue occurrence rate is 5%, is completely resistant to toxic chemotherapy drugs a patient.